Cue reactivity is conceptualized as sensitivity to cues linked with drug-taking experiences that contribute to craving and relapse in abstinent humans. Cue reactivity is modeled in rats by measuring attentional orientation toward drug-associated cues that results in appetitive approach behavior in a cue reactivity test following self-administration and forced abstinence.
Cocaine use disorder (CUD) follows a trajectory of repetitive self-administration during which previously neutral stimuli gain incentive value. Cue reactivity, the sensitivity to cues previously linked with the drug-taking experience, plays a prominent role in human craving during abstinence. Cue reactivity can be assessed as the attentional orientation toward drug-associated cues that is measurable as appetitive approach behavior in both preclinical and human studies. Herein describes an assessment of cue reactivity in rats trained to self-administer cocaine. Cocaine self-administration is paired with the presentation of discrete cues that act as conditioned reinforcers (i.e., house light, stimulus light, infusion pump sounds). Following a period of abstinence, lever presses in the cocaine self-administration context accompanied by the discrete cues previously paired with cocaine infusion are measured as cue reactivity. This model is useful to explore neurobiological mechanisms underlying cue reactivity processes as well as to assess pharmacotherapies to suppress cue reactivity and therefore, modify relapse vulnerability. Advantages of the model include its translational relevance, and its face and predictive validities. The primary limitation of the model is that the cue reactivity task can only be performed infrequently and must only be used in short duration (e.g., 1 hour), otherwise rats will begin to extinguish the pairing of the discrete cues with the cocaine stimulus. The model is extendable to any positively reinforcing stimulus paired with discrete cues; though particularly applicable to drugs of abuse, this model may hold future applications in fields such as obesity, where palatable food rewards can act as positively reinforcing stimuli.
Cocaine use disorder (CUD) follows a trajectory of repetitive self-administration during which previously neutral stimuli gain incentive value1. Cue reactivity is the sensitivity to cues previously linked with the drug-taking experience, and it plays a prominent role in human craving2,3,4,5. The risk of progression to CUD, as well as relapse during abstinence, is thought to be higher for individuals who express high sensitivity to drug-associated cues6,7. Both environmental contexts (e.g., people, buildings, music genres) and discrete drug-associated stimuli (e.g., paraphernalia) become associated with the cocaine reward; exposure to these cues can trigger changes in peripheral physiology (e.g., heart rate, skin temperature, and skin resistance), brain plasticity, and brain functional connectivity2,8,9,10. In other words, re-exposure to cocaine-associated cues activates limbic corticostriatal circuits to evoke conditioned physiological and subjective responses that drive appetitive approach (drug-seeking) behavior11,12,13,14,15.
Cue reactivity measured with functional brain imaging analyses is predictive of relapse vulnerability in subjects with CUD16. Cue reactivity measurements in rodent models serve as a surrogate measure for relapse risk and can be exploited for translational studies. Thus, a pharmacotherapy that decreases cue reactivity in rodents may be carried forward as a relapse-prevention treatment in human clinical trials. Preclinical models with the necessary translational merit and predictive validity are especially important since there are currently no FDA-approved pharmacotherapies for CUD17.
The rodent self-administration procedure is the gold standard, translational model with predictive validity for human drug-taking18 and critically important to understanding the molecular and physiological processes underlying CUD. Response-independent delivery of cocaine results in distinct behavioral, molecular, and neurochemical effects relative to response-dependent cocaine exposure; e.g., response-independent cocaine delivery evokes significantly higher mortality19. Furthermore, the neurochemical consequences of abstinence from response-dependent cocaine self-administration are distinct from those triggered by abstinence from response-independent cocaine delivery20,21. Thus, CUD models based upon response-dependent delivery of cocaine are superior translational models when assessing cue reactivity and associated mechanisms of action.
In the protocol outlined below, cocaine is delivered intravenously through an indwelling intra-jugular catheter. However, alternative methods to self-administer drug via oral and inhalation routes have been developed. Importantly, rodents control delivery of the drug, analogous humans, through operant responses. Therefore, there is high concordance between drugs self-administered by rodents and humans22. The preclinical drug self-administration procedure below employs lever pressing, reinforced by drug delivery, to motivate response rates higher than vehicle control. Drug-seeking behavior is trained by pairing originally "neutral" cues (e.g., a stimulus light or tone and the contextual environment in which cocaine self-administration occurs) with cocaine infusion; these cues become conditioned reinforcers (for review: Cunningham & Anastasio, 201423). Subsequent re-exposure to cocaine-associated cues triggers drug-seeking behavior in rodents (i.e., attempts to deliver cocaine through pressing on the previously-active lever) as well as craving and relapse in CUD subjects24,25,26,27.
Typically, preclinical rodent studies of drug-seeking behavior following cocaine self-administration utilize extinction training and/or drug reinstatement conducted within the drug-associated environment28,29,30,31,32. Presses on the previously-active lever, in the absence of drug and/or cue delivery, typically constitute the measure of reinstatement following extinction33,34,35. On the contrary, cue reactivity drug-seeking behavior is assessed following forced abstinence without prior extinction training28,36,37,38,39.
Outcome measures and experimental variables have been carefully chosen and validated to dissect different aspects of the neurobiology of drug-seeking and relapse-like behavior, and it is well-established that neuroadaptations differ between models with and without extinction training 40,41,42,43. Furthermore, from a translational perspective, rodent extinction training is not mirrored in clinical settings for CUD since drug-related cues include mood states, places, and people44; the unique combination of these cues are likely not available in a clinical environment45,46,47. Thus, the rodent model described herein acts as a better parallel to the human condition than many of the models currently available.
The following describes a validated cocaine self-administration training, forced abstinence and cue reactivity test protocol for rats. Briefly, rats are implanted with intra-jugular catheters, trained to self-administer cocaine or saline via 'active' lever press, and receipt of the cocaine or saline stimulus is paired with discrete light and sound cues which serve as conditioned reinforcers. Following 14 days of cocaine self-administration, rats are subjected to 30 days of forced abstinence and a subsequent 60-min cue reactivity test in which lever pressing is measured. The cue reactivity test is a surrogate measure for cocaine relapse vulnerability in humans.
All animal manipulations are carried out in accordance with the Guide for the Care and Use of Laboratory Animals (2011) and with approval from the Institutional Animal Care and Use Committee.
1. Animals
2. Surgery
3. Self-Administration
4. Forced Abstinence
5. Cocaine Cue Reactivity
6. Data Collection, Organization, and Analysis
Results of a cocaine self-administration and abstinence experiment followed by a cue reactivity test from a previously published study57 are shown in Figure 1. The study timeline is depicted in Figure 1A.
Rats individually transition from FR1 to FR5 as they meet criteria. As operant conditioning proceeds in the cocaine-administering group, rats gradually increase the number of infusions until they reach a plateau (Figure 1B). Inactive lever presses remain consistently low in both the cocaine-administering and saline-administering groups; differences in inactive lever presses suggest changes in motivation or health. Saline self-administration serves as a control in that saline is not reinforcing; thus, lever presses and infusions do not escalate from day 1 to day 14 (not pictured). If active lever presses in the cocaine-administering group decline between day 1 and day 14, the catheter has likely lost patency (also evidenced by the method described in Step 2.2.2), and this animal should be removed from the study. Animals that are statistical outliers (as calculated using a Dixon's Q Test) should also be removed from the study.
Multiple output measures are gathered from the cocaine cue reactivity test. For example, Figure 1C depicts the number of lever presses on the previously-active lever. Rats which previously self-administered cocaine should press the previously-active lever much more than rats which self-administered saline. And, if a treatment is effective at attenuating cocaine cue reactivity, there should also be a significant reduction in the number of previously-active lever presses in rats which received cocaine and the treatment compared to rats which received cocaine and the vehicle (not pictured).
Other measurements include latency to first lever press (Figure 1D), number of inactive lever presses, and number of cue presentations. Changes in latency to first lever press may be observed; an increased latency to first lever press may suggest that the animal is physically ill or that there is decreased motivation for cocaine. Appropriate controls for locomotor behavior, such as the Rotarod or Open Field tasks, should be employed to differentiate between physical illness and changes in motivation.
Although one might presume that the number of cue presentation should be reflected in the number of previously active lever presses, this is not often the case. Oftentimes previously-active lever presses are much greater than cue presentations. Rats often show perseverative previously-active lever pressing during the timeout period, ostensibly in response to a failure to receive the expected cocaine stimulus.
Figure 1. Experimental timeline and representative self-administration and cue reactivity results. This figure has been modified from Miller et al., 201657. (A) Experimental timeline as described in Protocol sections 3,4,5. (B) Average daily active lever presses, inactive lever presses, and infusions ± SEM for self-administration training; self-administration sessions were 180-min each day for 14 consecutive days. Cocaine was initially delivered on a FR1 schedule of reinforcement until meeting criterion, then a FR5 schedule was introduced. (C) Average lever presses on the previously-active lever press ± SEM for the 60-min cue reactivity test; an unpaired, two-tailed t-test shows a significant difference between cocaine and saline self-administering rats (t(30) = 14.82, **p <0.0001). (D) Average latency to first lever press ± SEM for the 60-min cue reactivity test; an unpaired, two-tailed t-test shows no significant difference between cocaine and saline self-administering rats (t(29) = 0.2758, p = 0.7847). Please click here to view a larger version of this figure.
Exposure to drug-paired cues and physiological changes in response to these cues16 are associated with relapse,11,16 and the cocaine cue reactivity test employed above contingently presents cocaine-paired cues in the absence of drug; thus, drug-seeking behavior in the form of previously-active lever presses serves as a measure of relapse vulnerability. The cue reactivity protocol described herein is a preclinical means by which relapse-modifying pharmacotherapies can be tested, and genetic and environmental factors that contribute to relapse risk can be investigated. This is an operant task for drug-seeking behavior that aligns with many properties of human drug-taking and relapse, and many publications have optimized key drug dose and delivery parameters as well as adopted appropriate controls to establish face validity and translational predictive power28,36,37,39,51. This model has recently been published in a study by Miller et al. investigating the use of a peroxisome proliferator-activated receptor gamma (PPARγ agonist as a pharmacotherapeutic to attenuate cocaine cue reactivity57. This study showed that pioglitazone (a PPARγ agonist) decreased responsiveness to cocaine-paired cues following forced abstinence from cocaine self-administration. Since pioglitazone is FDA-approved, the Miller et al. study prompted a two-arm, double-blind, randomized, placebo-controlled pilot clinical trial to examine the effectiveness of PPARγ agonism in suppressing cocaine cue reactivity, impulsivity, and risky decision-making. The translational merit and predictive validity of the rodent model is supported by the Schmitz et al. publication58 on this pilot study in which cocaine-dependent subjects treated with pioglitazone exhibited a treatment x time interaction for reduced self-reported craving as measured by the Brief Substance Craving Scale and a Visual Analog Scale for craving58.Thus, pioglitazone shows promise as a relapse prevention treatment for CUD, consistent with the Miller et al. preclinical data.
This rat cocaine cue reactivity test during abstinence recapitulates chronic human cocaine self-administration with intermittent short (e.g., 21 hour) and long (e.g., 30 day) abstinence periods, providing the ability to create parallel datasets between humans and rodent models. However, this protocol differs from the more pervasive extinction-reinstatement model which measures time to drug-taking or -seeking following an extinction process and (typically) an abstinence period33,34,35,59. Though the extinction-reinstatement model holds predictive validity33, it also has noteworthy limitations. First, the extinction process proceeds with re-exposing saline and cocaine self-administering groups to the self-administration context in the absence of drug reinforcement60 which is rarely recapitulated in humans since drug-related cues include mood states, places, and people44—cues which cannot be easily copied in a clinical setting45,46,47. Second, during the reinstatement process, rats exhibit low levels of responding creating a floor effect that suppresses one's ability to detect effects of interventions to reduce drug-seeking behavior33—an issue that is resolved by removing extinction since extinction training decreases responding. Some may argue that the 60-min cue reactivity test session described above could serve as an extinction session. However, the fact that the protocol includes non-drug reinforcement, the test session is not repeated, and rats maintain motivation for subsequent self-administration after cue reactivity testing suggests that this test design does not induce extinction36.
An additional issue is whether the relatively short self-administration session length employed (180-min) is sufficient to reinforce subsequent self-administration. However, literature shows that this regimen consistently results in a stable pattern of rat cocaine self-administration37,39,51,57,61, providing less variability between animals which allows the experimenter to sort subjects into post-self-administration treatment groups, if desired28,39,51,57. However, it should be noted that the short duration and short session length procedure does not entirely recapitulate human self-administration, where typically binge-like patterns emerge in cocaine-dependent subjects62. Nonetheless, if continuous self-administration is allowed in rodent models, mortality rates are extremely high63.
Additional variables to consider are cocaine dose and infusion rate since these influence sensitization of the subjective reward response. Faster speeds of infusion increase sensitization to the reinforcing effects of cocaine, while slower speeds decrease it64. Since the dose-dependence curve for cocaine self-administration is an inverted U shape and dose influences the number of infusions per hour55; the protocol above uses a dose which falls near the peak of the dose-response curve in both short-term access and long-term access procedures61 so as to detect shifts in the number of infusions. Counterbalancing the levers is another important control to ensure that the rats do not show preference for one lever over the other.
The representative results of Figure 1 show data from male, Sprague Dawley rats. Historically, these studies have been restricted to male rats because of the estrous cycle's effects on acquisition of cocaine self-administration65 and extinction/reinstatement66. Since sex as a biological variable is now mandated for NIH-funded studies, it has become imperative to monitor estrous stage and test for sex differences in mixed sex studies and, as such, statistical power must be considered for all experimental groups. On another note, use of an outbred rat strain, such as Sprague Dawley, is beneficial in that it provides genetic variation more comparable to the human population—though even outbred rodent strains may not fully recapitulate the diverse genetic influences thought to underlie addictive-like behaviors in humans67. Finally, age of initial cocaine exposure is an important consideration. In rats, exposure to cocaine during adolescence results in a conditioned place preference that requires a greater number of extinction trials to extinguish68, suggesting that the adolescent rat demonstrates greater persistence of cocaine-seeking behavior. Thus, prenatal and early postnatal exposure to cocaine will likely alter cocaine cue reactivity.
Because extinction is not the goal of cue reactivity testing, one limitation is that the task cannot be assessed repeatedly or over long durations, or else the animal will extinguish the pairing of the cocaine (primary) reinforcer with the discrete cue complex (conditioned reinforcers). Thus, care must be taken when designing the experiment to ensure that this extinction does not occur. However, an advantage of this task is that the precise biochemical changes induced by exposure to cocaine-paired cues can be elucidated using this procedure. A second limitation to the task is that it only works for positive reinforcers, though this is a limitation common to many models for drugs of abuse. Critical steps in the protocol include maintenance of catheter patency (Step 2.2), acquisition of self-administration (Step 3.2), appropriate distribution of rats into treatment groups, if desired, that are statistically equivalent for infusions and number of lever presses (Step 3.2.6), and proper software programming throughout to ensure that discrete cues are presented and paired with the cocaine stimulus during self-administration training and the cue reactivity test (Steps 3.1, 5.1). As with other relapse vulnerability models, it is imperative to achieve a reasonable length of abstinence to avoid floor and ceiling effects on responding during the cue reactivity test33,34 (Step 4). The most likely complications to encounter with this procedure are 1) loss of catheter patency preventing acquisition of self-administration, 2) improper distribution of rodents into treatment groups following self-administration training and prior to cue reactivity testing causing a Type 1 or Type 2 error, and 3) insufficient abstinence to determine differences in responding between groups. These can be resolved by daily assessment of self-administration performance, regular catheter flushes, assignment to post hoc analysis groups after balancing for self-administration performance, and pilot trials determining appropriate abstinence duration for rodent strain, age, self-administration session length and duration, drug, dose of drug, drug infusion duration, and sex.
This procedure is extendable to many rodent strains, including mice69, and any model which involves pairing of a primary rewarding reinforcer with discrete cues (conditioned reinforcers). Alternative primary reinforcers include other drug classes, high fat food, and other palatable rewards69,70. Finally, translational relevance of this model has been demonstrated by taking forward a FDA-approved intervention tested in rats to CUD human subjects which resulted in reduced cocaine craving. Thus, the cocaine cue reactivity test following cocaine self-administration and abstinence holds promise as a translational rodent model.
The authors have nothing to disclose.
All behavioral testing was performed in the University of Texas Medical Branch (UTMB) Rodent In Vivo Assessment (RIVA) Core, directed by Dr. Kelly Dineley and housed within the Center for Addiction Research, directed by Dr. Kathryn Cunningham. Support for this work came from the Peter F. McManus Charitable Trust, National Institute of Environmental Health Sciences Center for Environmental Toxicology at UTMB (T32ES007254), Institute for Translational Sciences at UTMB (UL1TR001439), Mitchell Center for Neurodegenerative Diseases, and Center for Addiction Research at UTMB (DA007287, DA070087, and pilot study funds).
Equipment | |||
Catheter Tubing: 0.50mm ID x 0.94mm OD x 0.2mm width | Fisher Scientific, Hampton, NH, USA | 11-189-15A | 1/experiment |
Cue Light | Med-Associates Inc. St. Albans, VT, USA | ENV-229M | 2/operant chamber |
Guide Cannulae (22 gauge, pedestal size-8mm, cut length 11 mm, 5 mm above the pedestal) | Plastics One, Roanoke, VA, USA | 8IC313G5UPXC | 1/rat |
House Light | Med-Associates Inc. St. Albans, VT, USA | ENV-227M | 1/operant chamber |
Infusion Pump | Med-Associates Inc. St. Albans, VT, USA | PHM-100 | 1/operant chamber |
Levers | Med-Associates Inc. St. Albans, VT, USA | ENV-110M | 2/operant chamber |
Liquid Swivels | Instech, Plymouth Meeting, PA, USA | 375/22 | 1/operant chamber |
MED-PC Package with Infusion Pump Software | Med-Associates Inc. St. Albans, VT, USA | SOF-735 (infusions software SOF-700RA-10 version 1.04) | 1 |
Metal Spring Leash | Plastics One, Roanoke, VA, USA | C313CS/SPC | 1/operant chamber |
Needle (23g, 1 in) | Becton Dickinson, Franklin Lakes, NJ, USA | 305193 | 1/operant chamber |
Nitex Mesh (6/6 woven mesh sheet, 12"x12", 500 microns thick, 38% Open Area) | Amazon, Seattle, WA, USA | CMN-0500-C, B000FMUNE6 | ~1 sheet/100 rats |
PCI Interface Package | Med-Associates Inc. St. Albans, VT, USA | DIG-700P2-R2, MED-SYST-16 | 1/16 operant chambers |
Power Supply for Interface Modules | Med-Associates Inc. St. Albans, VT, USA | SG-6510D | 1/16 operant chambers |
Sound-attenuating Cubicle | Med-Associates Inc. St. Albans, VT, USA | ENV-018V | 1/operant chamber |
Syringes, 10 mL Luer-Lok™ tip | Fisher Scientific, Hampton, NH, USA | 14-827-52 | 1 case/experiment (1/operant chamber) |
Tygon Tubing for flushes: 0.51mmID x 1.52mmOD 0.51mm thick x 152.4m | Fisher Scientific, Hampton, NH, USA | 14-170-15B | 1/experiment |
Chemicals | |||
Acepromazine (10mg/mL) | Henry Schein (Animal Health), Melville, NY, USA | 003845 | ~0.5mg/rat* |
Acraweld Repair Resin | Henry Schein (Dental), Melville, NY, USA | 1013959 | 1/experiment |
Altalube (ophthalmic ointment) | Henry Schein (Dental), Melville, NY, USA | 6050059 | 1/experiment |
Cocaine | NIDA North Bethesda, MD, USA | N/A | ~350mgs/rat for whole experiment*; requires DEA License |
Heparin (10,000 USP units/10 mL) | SAGENT Pharmaceuticals, Schaumburg, IL, USA | NDC 25021-400-10 | 1/experiment (~21 units/rat*) |
Jet Liquid | Henry Schein (Dental), Melville, NY, USA | 1256401 | 1/experiment |
Ketamine (100mg/mL, 10mL) | Henry Schein (Dental), Melville, NY, USA | 1049007 | ~15mg/rat*; requieres DEA license |
Methohexital Sodium (Brevital®, 500 mg/50 mL) | Patterson Dental, Saint Paul, MN, USA | 043-5461 | 1/experiment; requires DEA License |
Saline (0.9%, USP) | Baxter, Deerfield, IL, USA | 2B1307 | 1 case/experiment |
Streptokinase from β-hemolytic Streptococcus (Lancefield Group C) ≥3,000 units/mg | Sigma Aldrich, St. Louis, MO, USA | S3134-250KU | 1 vial/experiment (~1.5mg/rat/experiment*) |
Ticarcillin Disodium Salt | Fisher Scientific, Hampton, NH, USA | 50-213-695 | ~4 vials/exeriment or purchase the 25g vial cat.# 50-489-093 (~150mg/rat/experiment*) |
Xylazine (100mg/mL) | Henry Schein (Animal Health), Melville, NY, USA | 033198 | ~3mg/rat* |
*Assumes rat age is that described in the protocol, rats self-administer for 14 days, and flushes occur for 21 days. |